Literature DB >> 24795243

Definition and management of radioactive iodine-refractory differentiated thyroid cancer.

Martin Schlumberger1, Marcia Brose2, Rosella Elisei3, Sophie Leboulleux4, Markus Luster5, Fabian Pitoia6, Furio Pacini7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24795243     DOI： 10.1016/S2213-8587(13)70215-8

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN： 2213-8587            Impact factor:   32.069


× No keyword cloud information.
  80 in total

Review 1.  Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer.

Authors:  Francis Worden
Journal:  Ther Adv Med Oncol       Date:  2014-11       Impact factor: 8.168

Review 2.  Endocrinology research-reflecting on the past decade and looking to the next.

Authors:  Kevan C Herold; Joseph A Majzoub; Shlomo Melmed; Merri Pendergrass; Martin Schlumberger
Journal:  Nat Rev Endocrinol       Date:  2015-10-13       Impact factor: 43.330

3.  Cytopathology of Follicular Cell Nodules.

Authors:  Domenico Damiani; Voichita Suciu; Philippe Vielh
Journal:  Endocr Pathol       Date:  2015-12       Impact factor: 3.943

Review 4.  2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer.

Authors:  Laura Fugazzola; Rossella Elisei; Dagmar Fuhrer; Barbara Jarzab; Sophie Leboulleux; Kate Newbold; Jan Smit
Journal:  Eur Thyroid J       Date:  2019-08-28

5.  Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.

Authors:  Marcia S Brose; Christopher M Nutting; Barbara Jarzab; Rossella Elisei; Salvatore Siena; Lars Bastholt; Christelle de la Fouchardiere; Furio Pacini; Ralf Paschke; Young Kee Shong; Steven I Sherman; Johannes W A Smit; John Chung; Christian Kappeler; Carol Peña; István Molnár; Martin J Schlumberger
Journal:  Lancet       Date:  2014-04-24       Impact factor: 79.321

6.  Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib.

Authors:  Vincenzo Marotta; Concetta Sciammarella; Mario Capasso; Alessandro Testori; Claudia Pivonello; Maria Grazia Chiofalo; Rosario Pivonello; Luciano Pezzullo; Gerardo Botti; Annamaria Colao; Antongiulio Faggiano
Journal:  Endocrine       Date:  2016-12-16       Impact factor: 3.633

7.  Concurrent metastases of papillary thyroid carcinoma to the scalp and Meckel's cave.

Authors:  Patrick S Phelan; Jamie L Mull; Mohamed Z Rajput; Amy C Musiek
Journal:  BMJ Case Rep       Date:  2018-06-17

8.  Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.

Authors:  Weibin Wang; Helen Kang; Yinu Zhao; Irene Min; Brian Wyrwas; Maureen Moore; Lisong Teng; Rasa Zarnegar; Xuejun Jiang; Thomas J Fahey
Journal:  J Clin Endocrinol Metab       Date:  2017-02-01       Impact factor: 5.958

Review 9.  Immunotherapy for advanced thyroid cancers - rationale, current advances and future strategies.

Authors:  Jena D French
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330

10.  Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study.

Authors:  Christelle de la Fouchardiere; Nadia Oussaid; Olfa Derbel; Myriam Decaussin-Petrucci; Marie-Eve Fondrevelle; Qing Wang; Pierre-Paul Bringuier; Claire Bournaud-Salinas; Jean-Louis Peix; Jean-Christophe Lifante; Anne-Laure Giraudet; Jonathan Lopez; Françoise Borson-Chazot
Journal:  Target Oncol       Date:  2016-02       Impact factor: 4.493
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.